Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | YWHAG | P61981 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | FSHR | P23945 | 1/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994565 | 0.89 | NR1H2 (0.39) | NR1H2BRD4ATAD2HSD17B3KDM4E | |
| SCHEMBL14575084 | 0.86 | ATAD2 (0.44) | NR1H2BRD4ATAD2HSD17B3GFER | |
| SCHEMBL29014075 | 0.83 | LMNA (0.38) | BRD4HSD17B3GFERMEN1KMT2A | |
| SCHEMBL3796963 | 0.79 | NOTUM (0.51) | NOTUMALDH1A1 | |
| SCHEMBL29014085 | 0.75 | CRBN (0.42) | KDM4EALDH1A1 | |
| SCHEMBL14321151 | 0.74 | PDK1 (0.39) | BRD4HSD17B3KDM4EMAPTMEN1 | |
| SCHEMBL5798751 | 0.72 | NOTUM (0.62) | BRD4ATAD2HSD17B3KDM4EMAPT | |
| SCHEMBL17058884 | 0.69 | NR1H2 (0.35) | NR1H2BRD4ATAD2 | |
| SCHEMBL19739177 | 0.69 | NR1H2 (0.48) | NR1H2BRD4ATAD2MEN1KMT2A | |
| SCHEMBL19739175 | 0.69 | NR1H2 (0.48) | NR1H2BRD4ATAD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188120-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110212930-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-01 | — | — | US | disclosed |
| US-7960411-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100119510-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| US-7691846-B2 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[5-(2-oxo-1-piperidinyl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090176758-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[5-(2-oxo-1-piperidinyl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-09 | — | — | US | disclosed |
| US-7115627-B2 | Glycinamides as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1465892-A4 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1465892-A1 | GLYCINAMIDES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030232804-A1 | Glycinamides as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048158-A1 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232804-A1 | Glycinamides as factor Xa inhibitors | F11, F13B, F12 | NR1H2 2780/4885BRD4 4471/4885ATAD2 3800/4885 |
| US-20110212930-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | NR1H2 3725/4885BRD4 1600/4885ATAD2 2657/4885 |
| US-20090176758-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[5-(2-oxo-1-piperidinyl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | F2, PLAT, TFPI | NR1H2 3980/4885BRD4 237/4885ATAD2 2766/4885 |
| US-20100119510-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | NR1H2 3725/4885BRD4 1600/4885ATAD2 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.